Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), announces the retirement of its Managing Director Thomas Otto after more than 35 years at the company. He will step down at the end of 2025.

Through his clear leadership and commitment, Thomas Otto has been instrumental in shaping the sustainable development and continued growth of the company. As a partner to global biopharmaceutical companies for the production of life-enhancing medicines, Vetter’s success is partially due to his strong and reliable leadership alongside his management colleagues.

“Thomas Otto has decisively advanced our family business with his vision, innovative strength and great sense of responsibility. His contribution to Vetter’s development and internationalization is outstanding and deserves the highest recognition,” says Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the owner family. “For more than three decades, he was a reliable designer, initiator and bridge builder – both within the company and externally. On behalf of the Vetter family and the advisory board, I would like to thank him for his extraordinary commitment and lasting impact on our success story.”

“I am grateful for the many years at Vetter and proud of what we have achieved together. I am extremely pleased that I was able to contribute to making the company strong and fit to take on the future. I wish my colleagues in the management team continued success in leading Vetter with competence and passion,” shared Thomas Otto.

In his advisory role, he will contribute his extensive knowledge and decades of experience with pharmaceutical construction projects to the planned development of a new production site in Germany.

Strategic Succession Planning Ensures Continuity

The strategic planning for the new structure of the Vetter management team already started earlier. Long-term experienced Vetter executives Henryk Badack, Titus Ottinger and Carsten Press were appointed to the Management Board as Managing Directors at the beginning of 2025. With their in-depth understanding of the company, its customers and the industry, they are making a significant contribution to Vetter’s sustainable future and the trust towards the owner family and the company Advisory Board.

Vetter remains a trusted partner for its customers, employees, partners and the region. The globally active CDMO continues to stand for quality and stability, strong partnerships and sustainable development. In close collaboration with its customers, the company significantly contributes that life-enhancing medicines are readily available to help patients around the world achieve a better quality of life.